Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Number of Shares and Votes in Orexo

Posted on: 30 Sep 16

The number of shares and votes in Orexo AB (STO:ORX) has changed as a result of the exercise of warrants in connection with the company’s incentive programs.

Today, the last trading day of the month, there are in total 34,666,107 shares - whereof 34,531,107 are ordinary shares and 135,000 class C shares - and 34,544,607 votes in the company.

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.

For more information about Orexo, please visit or follow us on Twitter or LinkedIn. For further information about Zubsolv in the US, please visit

The information was submitted for publication at 6:00pm CET, September 30, 2016

This information was brought to you by Cision

View source version on

Business Wire

Last updated on: 30/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.